Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Mahsa Eskian, MirHojjat Khorasanizadeh, Pier Luigi Zinzani, Tim M. Illidge & Nima Rezaei. (2019) Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma. International Reviews of Immunology 38:2, pages 79-91.
Read now
Read now
Clémentine Sarkozy, Gilles Salles & Emmanuel Bachy. (2015) Chemotherapy-free treatment in patients with follicular lymphoma. Expert Review of Hematology 8:2, pages 187-203.
Read now
Read now
Nelson Leung & Thomas E. Witzig. (2013) The use of 90yttrium-ibritumomab tiuxetan in patients on dialysis: what do we know regarding its pharmacokinetics?. Leukemia & Lymphoma 54:12, pages 2586-2587.
Read now
Read now
Clémentine Sarkozy & Gilles Salles. (2013) Treatment approaches to asymptomatic follicular lymphoma. Expert Review of Hematology 6:6, pages 747-758.
Read now
Read now
Andrew Wirth & Michael S. Hofman. (2012) Special delivery: getting radiation to the target in diffuse large B-cell lymphoma. Leukemia & Lymphoma 53:5, pages 751-753.
Read now
Read now
Articles from other publishers (26)
George Sgouros, Wesley E. Bolch, Arturo Chiti, Yuni K. Dewaraja, Dimitris Emfietzoglou, Robert F. Hobbs, Mark Konijnenberg, Katarina Sjögreen-Gleisner, Lidia Strigari, Tzu-Chen Yen & Roger W. Howell. (2022) ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy. Journal of the ICRU 21:1, pages 1-212.
Crossref
Crossref
Mengyang Di, Thomas A. Ollila & Adam J. Olszewski. (2020) Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study. Leukemia 34:10, pages 2794-2797.
Crossref
Crossref
Frederick Lansigan, Cristiana A. Costa, Bassem I. Zaki, Stephanie P. Yen, Eric S. Winer, Helen Ryan, Darcie Findley, Sara R. Metzler, Lynn Shaw, Bonnie Toaso, Todd A. MacKenzie, Youdinghuan Chen & Anne W. Beaven. (2019) Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe). Clinical Cancer Research 25:20, pages 6073-6079.
Crossref
Crossref
Eva U. Spukti, Lars Henning Schmidt, Arik Schulze, Christoph Schliemann, Dennis Görlich, Eva Wardelmann, Wolfgang Hartmann, Georg Lenz, Wolfgang E. Berdel & Andrea Kerkhoff. (2018)
90
Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single-center experience
. European Journal of Haematology 101:4, pages 514-521.
Crossref
Crossref
Sean Carlin. (2018) Penetrating the Barriers to Successful α-Radioimmunotherapy. Journal of Nuclear Medicine 59:6, pages 934-936.
Crossref
Crossref
Curtiland DevilleJr.Jr., Gaurav Shukla, Ramesh Rengan & Charles R. ThomasJr.Jr.. 2018. The American Cancer Society's Principles of Oncology. The American Cancer Society's Principles of Oncology
204
219
.
Narendranath Epperla, Anthony Q. Pham, Brian L. Burnette, Gregory A. Wiseman, Thomas M. Habermann, William R. Macon, Stephen M. Ansell, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Svetomir N. Markovic, Luis F. Porrata, Joseph P. Colgan, Kay M. Ristow, Grzegorz S. Nowakowski & Thomas E. Witzig. (2017) Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. British Journal of Haematology 178:3, pages 427-433.
Crossref
Crossref
L Bento, A Boumendil, H Finel, S Le Gouill, S Amorim, H Monjanel, R Bouabdallah, J O Bay, E Nicolas-Virelizier, G McQuaker, G Rossi, R Johnson, A Huynh, P Ceballos, A Rambaldi, E Bachy, R Malladi, K Orchard, D Pohlreich, H Tilly, F Bonifazi, X Poiré, F Guilhot, A Haenel, C Crawley, B Metzner, J Gribben, N H Russell, G Damaj, K Thomson, P Dreger & S Montoto. (2017) Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party. Bone Marrow Transplantation 52:8, pages 1120-1125.
Crossref
Crossref
Tarik Hadid, Ali Raufi, Zyad Kafri, Mary Mandziara, John Kalabat, Susan Szpunar, Kleanthe Kolizeras, Mary Steigelman & Ayad Al-Katib. (2016) Safety and efficacy of radioimmunotherapy (RIT) in treatment of non-Hodgkin's lymphoma in the community setting. Nuclear Medicine and Biology 43:4, pages 227-231.
Crossref
Crossref
T.E. Witzig, G.S. Nowakowski, T.M. Habermann, A. Goy, F.J. Hernandez-Ilizaliturri, A. Chiappella, U. Vitolo, N. Fowler & M.S. Czuczman. (2015) A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Annals of Oncology 26:8, pages 1667-1677.
Crossref
Crossref
Chadi Nabhan, Michelle Byrtek, Ashish Rai, Keith Dawson, Xiaolei Zhou, Brian K. Link, Jonathan W. Friedberg, Andrew D. Zelenetz, Matthew J. Maurer, James R. Cerhan & Christopher R. Flowers. (2015) Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. British Journal of Haematology 170:1, pages 85-95.
Crossref
Crossref
Damian J. Green, Mazyar Shadman, Jon C. JonesShani L. FrayoAimee L. KenoyerMark D. Hylarides, Donald K. HamlinD. Scott WilburEthan R. Balkan, Yukang Lin, Brian W. Miller, Sofia H. L. Frost, Ajay K. Gopal, Johnnie J. Orozco, Theodore A. Gooley, Kelly L. LairdBrian G. Till, Tom Bäck, Brenda M. Sandmaier, John M. Pagel & Oliver W. Press. (2015) Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. Blood 125:13, pages 2111-2119.
Crossref
Crossref
Emmanuel Bachy & Gilles Salles. (2014) Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma?. Clinical Cancer Research 20:20, pages 5226-5239.
Crossref
Crossref
Thaddeus J. WadasDarpan N. PandyaKiran Kumar Solingapuram SaiAkiva Mintz. (2014) Molecular Targeted α-Particle Therapy for Oncologic Applications. American Journal of Roentgenology 203:2, pages 253-260.
Crossref
Crossref
Karin Hohloch, H. K. Lankeit, P. L. Zinzani, C. W. Scholz, M. Lorsbach, C. Windemuth-Kieselbach & L. Trümper. (2014) Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network. European Journal of Nuclear Medicine and Molecular Imaging 41:8, pages 1585-1592.
Crossref
Crossref
Qichun Wei, Jing Xu, Li Shen, Xianhua Fu, Bicheng Zhang, Xiaofeng Zhou & Jorgen Carlsson. (2014) HER2 expression in primary gastric cancers and paired synchronous lymph node and liver metastases. A possible road to target HER2 with radionuclides. Tumor Biology 35:7, pages 6319-6326.
Crossref
Crossref
Chaitanya Divgi. (2014) Whither Goest Thou, Radiopharmaceutical Therapy?. Journal of Nuclear Medicine 55:1, pages 5-6.
Crossref
Crossref
M.R. Jackson, N. Falzone & K.A. Vallis. (2013) Advances in Anticancer Radiopharmaceuticals. Clinical Oncology 25:10, pages 604-609.
Crossref
Crossref
Robert F. Hobbs, Richard L. Wahl, Eric C. Frey, Yvette Kasamon, Hong Song, Peng Huang, Richard J. Jones & George Sgouros. (2013) Radiobiologic Optimization of Combination Radiopharmaceutical Therapy Applied to Myeloablative Treatment of Non-Hodgkin Lymphoma. Journal of Nuclear Medicine 54:9, pages 1535-1542.
Crossref
Crossref
Thomas E. Witzig, Gregory A. Wiseman, Matthew J. Maurer, Thomas M. Habermann, Ivana N.M. Micallef, Grzegorz S. Nowakowski, Stephen M. Ansell, Joseph P. Colgan, David J. Inwards, Luis F. Porrata, Brian K. Link, Clive S. Zent, Patrick B. Johnston, Tait D. Shanafelt, Cristine Allmer, Yan W. Asmann, Mamta Gupta, Zuhair K. Ballas, Brian J. Smith & George J. Weiner. (2013)
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and
90
yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma
. American Journal of Hematology 88:7, pages 589-593.
Crossref
Crossref
Thomas E. Witzig. (2013) Moving Radioimmunotherapy Forward for Follicular Lymphoma. Journal of Clinical Oncology 31:3, pages 294-296.
Crossref
Crossref
Oliver W. PressJoseph M. UngerLisa M. RimszaJonathan W. FriedbergMichael LeBlancMyron S. CzuczmanMark KaminskiRita M. BrazielCatherine SpierAjay K. GopalDavid G. MaloneyBruce D. ChesonShaker R. DakhilThomas P. MillerRichard I. Fisher. (2013)
Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus
131
Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016
. Journal of Clinical Oncology 31:3, pages 314-320.
Crossref
Crossref
Edward N Libby. (2012) Diagnosis and treatment of follicular lymphoma: where do we stand?. International Journal of Hematologic Oncology 1:2, pages 169-178.
Crossref
Crossref
Richard Van der Jagt. (2012) Management of patients with relapsed/refractory follicular lymphoma. Community Oncology 9:11, pages S61-S67.
Crossref
Crossref
Matthew A. Lunning & Julie M. Vose. (2012) Management of indolent lymphoma: Where are we now and where are we going. Blood Reviews 26:6, pages 279-288.
Crossref
Crossref
Roswitha Forstpointner & Martin Dreyling. (2011) Rituximab Maintenance Versus Radioimmunotherapy Consolidation in Follicular Lymphoma: Which, When, and for Whom?. Current Hematologic Malignancy Reports 6:4, pages 207-215.
Crossref
Crossref